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Abstract Purpose: To illustrate
the impact on the validity of trial
results due to excluding patients from
a randomized controlled trial for
whom no deferred consent could be
obtained after randomization because
study procedures had already been
ﬁnished. Methods: The unadjusted
and adjusted primary outcome mea-
sures of a recent randomized
controlled multicentre study in the
ﬁeld of intensive care medicine were
compared, including (n = 348) or
excluding (n = 289) patients with
missing deferred consent. Results:
Thirty-nine patients (11%) died early,
before the patient or his/her proxy
could be approached and consent be
obtained. In another 20 patients (6%),
it was not possible to inform proxies
and ask consent within the period of
study procedures. A signiﬁcant treat-
ment effect (p = 0.006) in the
adjusted analysis became non-signif-
icant (p = 0.35) when the patients
with missing deferred consent were
excluded. Conclusions: Exclusion
of patients without obtained deferred
consent can reduce statistical power,
introduce selection bias, make ran-
domization asymmetrical, decrease
external validity and thereby jeopar-
dize study results. This may have
implications for emergency research
in various disciplines.
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Introduction
Respect for individual autonomy, expressed in the con-
cept of informed consent, is a basic ethical principle in
research with humans. Many critically ill patients are
unable to give consent as a consequence of mental
incapacity, and this can be further complicated in
emergency situations, in which treatment needs to be
initiated without delay. Proxies are not always available
in the ﬁrst hours of hospital or intensive care admission
or are too overwhelmed to understand the provided
information to give valid consent. Deferred consent is an
acceptable substitute in these emergency circumstances
[1]. However, clinicians and investigators may encoun-
ter an important practical and ethical problem after
enrolling patients under deferred consent: should the
researcher use the study data if study procedures have
already been ﬁnished before it was possible to inform
the patient or his/her proxy and ask consent? This
includes the situation in which the patient has died early.
The intention-to-treat principle implies that the pri-
mary analysis should include all subjects. Compliance
with this principle would necessitate complete follow-up
of all subjects for study outcomes. As patients who die
early are the most severely ill, excluding them could
reduce external validity, jeopardize the balance between
study arms and inﬂuence the effect of the intervention
[1, 2].
In an earlier discussion paper, we argued that deferred
proxy consent is the preferable substitute for informed
consent in emergency critical care research. In case of the
situation when study procedures are ﬁnished or the patient
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use the study data that have already been obtained, pro-
vided sufﬁcient privacy measures have been applied.
Several arguments support this recommendation. First,
using data of patients who died and for whom deferred
consent was not yet obtained will not harm the patient or
relatives. Second, confronting bereaved relatives to obtain
consent after death of the patient is an additional burden.
Third, using data will beneﬁt future patients and society.
Fourth, the Dutch Central Committee on Research
involving Human Subjects (CCMO) stated that the
research has ended with the death of the patient and rel-
atives do not have the legal right to give consent for the
use of medical data after the patient has died. Finally and
most importantly, not using the data will probably jeop-
ardize validity of study results [2].
To support the latter argument, we compared the
results of a recent randomized controlled multicentre
study in the ﬁeld of intensive care medicine [3], including
or excluding data from patients where study procedures
were already ﬁnished before consent could be obtained.
We hypothesize that not using these data will reduce
internal and external validity.
Methods
In the example study, patients with hyperlactatemia on
intensive care admission were randomly allocated to
either the lactate group or the control group. In the lactate
group, resuscitation therapy was guided by blood lactate
levels with the objective to decrease lactate levels by 20%
or more per 2 h, during the ﬁrst 8 h of intensive care stay.
In the control group the treatment team had no knowledge
of lactate levels (except for the admission value). Because
of the emergency nature and severity of disease in the
target population, patients were enrolled under deferred
(proxy) consent: study procedures were temporarily
allowed without consent and, as soon as possible, written
consent from the patient or legal representative was
obtained. In-hospital mortality was the primary outcome
measure. This primary outcome was compared between
the two randomization groups using the chi-square test
and using predeﬁned multivariate Cox proportional-haz-
ards analysis, stratiﬁed by centre and sepsis group, where
adjustment was made for the following co-variables: age,
sex, baseline Acute Physiology and Chronic Health
Evaluation II (APACHE II) and baseline Sequential
Organ Failure Assessment (SOFA) score [4]. We com-
pared the primary outcome measures in the study
population with or without patients where study proce-
dures were already ﬁnished before consent could be
obtained.
Results
The study population consisted of 348 patients; 39
patients (11%) died early, before the patient or his/her
proxy could be approached and consent be obtained. In
another 20 patients (6%), it was not possible to inform
proxies and ask consent within the period of study pro-
cedures (no family available, non-Dutch-speaking family,
transfer to other hospital etc.). Table 1 presents baseline
characteristics according to obtained consent status. There
were more patients with missing consent due to early
death in the control group than in the lactate group [14.7%
(26/177) versus 7.6% (13/171), p = 0.042]. The number
of patients in each group with missing consent due to
other reasons (than early death) was similar [control
group 6.8% (12/177) versus lactate group 4.7% (8/171),
p = 0.492].
Table 2 presents the results of the unadjusted and
adjusted primary outcome analyses. A signiﬁcant treat-
ment effect (p = 0.006) in the adjusted analysis even
became non-signiﬁcant (p = 0.35) when patients with
missing deferred consent were excluded. In addition,
when adding the variable ‘‘missing consent’’ to the mul-
tivariable Cox proportional-hazards model, the treatment
effect of lactate-guided therapy was reduced from 0.006
to 0.063. When adding the variable ‘‘missing consent due
to early death’’, the p value was reduced to 0.210. When
calculating interaction, we could not demonstrate a sig-
niﬁcant difference in the unadjusted treatment effect
between those with and without missing consent.
Discussion
As illustrated by the data, excluding patients for whom no
deferred consent can be obtained after randomization may
result in invalid study results. In our study, a signiﬁcant
adjusted treatment effect became non-signiﬁcant when
excluding patients with missing deferred consent. This
phenomenon can be ascribed to two different reasons.
First, it is the effect of a lack of power due to the reduced
sample size in combination with altered mortality rates.
This can be illustrated when calculating the actual power
in the two populations. Based on an unadjusted absolute
mortality reduction from 43.5 to 33.9% in the entire
sample size of 348 patients, the calculated power was
45%. This was reduced to 12% when excluding all
patients with missing deferred consent (sample size 289
patients, absolute mortality reduction from 33.1 to
28.7%). The second reason is the likely introduction of
selection bias. Furthermore, because patients with missing
consent were more severely ill, this means that, by
excluding these patients, the study population will no
1963longer be representative of the actual population deﬁned
by the inclusion and exclusion criteria.
Notably, more patients in the control group had
missing consent due to early death than in the lactate
group. The baseline characteristics presented in Table 1
show that patients lacking consent were indeed more
severely ill. Furthermore, while missing consent due to
early death was more frequent in the control group, the
proportion of missing consent not due to death was sim-
ilar between the treatment groups. This suggests that the
difference in ‘‘obtained consent status’’ was probably not
related to a more systematic search for consent in the
lactate group due to the open-label study design, but to a
matter of time before the patient’s death.
In conclusion, exclusion of patients with missing
informed consent, because study procedures have already
been ﬁnished before it was possible to obtain consent, can
reduce statistical power, introduce selection bias, make
randomization asymmetrical, decrease external validity
and thereby jeopardize study results. In addition, very few
Table 1 Baseline characteristics according to consent status
Variable Obtained consent
(N = 289)
Missing consent
(N = 59)
p Value
Age (years) 61 ± 17 66 ± 17 0.042
Male sex, n (%) 177 (61) 44 (75) 0.053
Median (interquartile range) time from arrival at hospital to randomization, h 8 (1–78) 3 (1–78) 0.90
ICU admission within 6 h from hospital admission, n (%) 139 (48) 38 (59) 0.022
Median (interquartile range) time from ICU admission to randomization, h 0.6 (0.2–1.3) 0.5 (0.2–0.8) 0.089
APACHE II score 22.3 ± 8.7 27.5 ± 8.7 \0.001
SOFA score 8.6 ± 3.9 10.3 ± 4.4 0.003
Diagnostic category, n (% of patients in the consent group)
Sepsis category: 113 (39) 22 (37) 0.020*
Severe sepsis 58 (20) 11 (19)
Septic shock 55 (19) 11 (19)
Non-sepsis category: 176 (61) 37 (63)
Neurologic 31 (11) 6 (10)
Cardiac arrest 32 (11) 16 (27)
Other non-sepsis 113 (39) 15 (25)
Hospital, n (% of patients in the consent group)
Hospital I 159 (55) 37 (63) 0.15
Hospital II 40 (14) 12 (20)
Hospital III 26 (9) 3 (5)
Hospital IV 64 (22) 7 (12)
Referring department, n (% of patients in the consent group)
Operation theatre (acute surgery) 75 (26) 18 (31) 0.31
Operation theatre (elective surgery) 39 (14) 3 (5)
Ward or emergency department 161 (56) 36 (61)
Other ICU 13 (5) 2 (3)
Treated with metformin 12 (4) 3 (5) 0.75
Treated with anti-retroviral therapy 2 (1) 0 (0) 1.0
Median (interquartile range) blood lactate level (mEq/l) 4.3 (3.5-5.8) 5.2 (3.8-8.0) 0.006
Central venous oxygen saturation (%) 72 ± 12 74 ± 8 0.45
Values are mean ± standard deviation (SD) unless otherwise speciﬁed
* p-Value for comparison between severe sepsis, septic shock, neurologic, cardiac arrest and other non-sepsis subgroups
Table 2 Mortality with and without patients with missing deferred consent
Control group Lactate group Relative risk (95% CI) p-Value
In-hospital mortality: unadjusted analysis, % (n)
All patients (n = 348) 43.5 (77/177) 33.9 (58/171) 0.78 (0.60-1.02) 0.067
Excluding early death (n = 309) 33.8 (51/151) 28.5 (45/158) 0.84 (0.60-1.18) 0.32
Excluding all missing deferred consent (n = 289)* 33.1 (46/139) 28.7 (43/150) 0.87 (0.61-1.22) 0.42
In-hospital mortality: adjusted analysis, hazard ratio (95% CI)
All patients (n = 348) 0.61 (0.43-0.87) 0.006
Excluding early death (n = 309) 0.80 (0.53-1.21) 0.28
Excluding all missing deferred consent (n = 289) 0.81 (0.53-1.25) 0.35
* p-Value for interaction between consent status (missing or obtained consent) and treatment effect (Breslow–Day test of homogeneity):
0.59
1964patients or relatives refuse consent for use of already
obtained data in emergency situations [1, 3]. Therefore,
not using data from patients in whom study procedures
have been completed and deferred consent has not been
obtained is unethical and, in addition, will be unjust to
patients and proxies who have consented for use of data.
These ﬁndings may have important implications for
emergency research in disciplines ranging from intensive
care and emergency medicine to cardiology and (trauma)
surgery.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are
credited.
References
1. Jansen TC, Kompanje EJO, Bakker J
(2009) Deferred consent in emergency
critical care research: ethically valid and
practically feasible. Crit Care Med
37:S65–S68
2. Jansen TC, Kompanje EJO, Druml C,
Menon DK, Wiederman CJ, Bakker J
(2007) Deferred consent in emergency
intensive care research: what if the
patient dies early? Use the data or not?
Intensive Care Med 33:894–900
3. Jansen TC, van Bommel J,
Schoonderbeek J, Sleeswijk Visser S,
van der Klooster J, Lima AP, Willemsen
SP, Bakker J (2010) Early lactate-guided
therapy in ICU patients: a multicentre,
open-label randomized controlled trial.
Am J Respir Crit Care Med [Epub ahead
of print]
4. Roozenbeek B, Maas AIR, Lingsma HF,
Butcher I, Lu J, Marmarou A, McHugh
GS, Weir J, Murray GD, Steyerberg EW
(2009) Baseline characteristics and
statistical power in randomized
controlled trials: selection, prognostic
targeting, or covariate adjustment? Crit
Care Med 37:2683–2690
1965